Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharmHKSE:01498 23 EBITDA Margin % is 13.37% as of Dec. 2025, which is 45% above its 10-year median of 9.21. GuruFocus rates HKSE:01498 with a GF Score™ of 23/100 and a GF Value™ of HK$0.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 957 Drug Manufacturers companies, PuraPharm ranks worse than 58.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PuraPharm's EBITDA for the
six
months ended in Dec. 2025 was HK$21.9 Mil. PuraPharm's Revenue for the
six
months ended in Dec. 2025 was HK$163.8 Mil. Therefore, PuraPharm's EBITDA margin for the quarter that ended in Dec. 2025 was 13.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PuraPharm EBITDA Margin % Related Terms
PuraPharm EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PuraPharm's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PuraPharm EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PuraPharm's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PuraPharm's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a EBITDA Margin % of 13.37% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PuraPharm and its competitors. This is 45% above median its historical median of 9.21. According to the industry distribution chart, PuraPharm ranks #561 out of 957 companies in the Drug Manufacturers industry, placing it in the top 58.6%.
Is PuraPharm's EBITDA Margin % too high?
PuraPharm's current EBITDA Margin % of 13.37% is 45% above median its 10-year median of 9.21. The Drug Manufacturers industry median EBITDA Margin % is 12.14. PuraPharm's value of 13.37% is 10.1% above this industry median. Based on the distribution chart, PuraPharm ranks #561 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PuraPharm ranks #561 out of 957 companies for EBITDA Margin %. This places PuraPharm in the lower half of its industry. The industry median EBITDA Margin % is 12.14. PuraPharm's value of 13.37% is 10.1% above this benchmark. While the company's 10-year median is 9.21 vs. the industry median of 12.14, PuraPharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.14, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PuraPharm's current EBITDA Margin % of 13.37% is 10.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PuraPharm and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PuraPharm's current EBITDA Margin % is 13.37%, which is 45% above median its own 10-year median of 9.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current EBITDA Margin % is 13.37%, which is 45% above median its 10-year median of 9.21 and 10.1% above the Drug Manufacturers industry median of 12.14. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current EBITDA Margin % is 13.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
EBITDA Margin %: 13.37% (45% above median its 10-year median of 9.21)
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
Industry Position: 10.1% above the Drug Manufacturers median (#561 of 957)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
